A single daily pill combining bictegravir and lenacapavir could help simplify complex treatment regimens for HIV patients. Most people with HIV take one pill a day or an injection twice a month, but some with resistant virus, often older adults on long-term treatment, take up to 11 pills a day. The Phase 3 study in the Lancet included 557 people with HIV-1 from 15 countries who had low viral loads below 50 copies/ml and comprehensive regimens, with a third taking four or more pills a day. The results showed that the new combination maintained virologic suppression and was comparable to existing regimens. In the ARTISTRY-1 study at week 48, 0.8% of participants on BIC/LEN had HIV-1 RNA ≥50 copies/mL versus 1.1% on combination regimens. The combination of bictegravir (75 mg) and lenacapavir (50 mg) was generally well tolerated with no new safety issues. This option could expand treatment alternatives for virologically suppressed patients on complex regimens.